Skip to main content

Together we are beating cancer

Donate now

Cancer News

Immunotherapy

Showing 12 out of 215 results
Cancer Research UK logo

Cancer Research Technology, the commercial arm of Cancer Research UK, has signed a license agreement to grant antibody medicines company, Affitech A/S, (NASDAQ OMX: AFFI), exclusive rights to a CRT patent application and relevant know how to develop and use therapeutic antibodies that recognise and block the function of CCR4, a protein found on certain tumours - including early and late stage cervical cancer and oesophageal cancer. Cancer Research Technology, the commercial arm of Cancer Research UK, has signed a license agreement to grant antibody medicines company, Affitech A/S, (NASDAQ OMX: AFFI), exclusive rights to a CRT patent application and relevant know how to develop and use therapeutic antibodies that recognise and block the function of CCR4, a protein found on certain tumours - including early and late stage cervical cancer and oesophageal cancer.

by Cancer Research Technology (CRT) | News | 27 April 2011

27 April 2011